Alembic Pharmaceuticals Reports Robust Q2 FY27 Results with 81% PAT Growth
Alembic Pharmaceuticals Ltd 路 Press Release 路 04 Nov 2026, 8:04 pm
Alembic Pharmaceuticals Reports Robust Q2 FY27 Results with 81% PAT Growth Alembic Pharmaceuticals reported a strong performance for Q2 FY27 ended 30th Sep'26, with consolidated revenue rising 36% YoY to Rs 2,603 Cr. EBITDA grew 78% YoY to Rs 578 Cr with a 22% margin, while PAT jumped 81% YoY to Rs 335 Cr. Growth was driven by US Formulations, which surged 77% YoY to Rs 1,003 Cr backed by three new launches. API revenue expanded 39% YoY to Rs 436 Cr, India Formulations grew 14% to Rs 725 Cr, and Ex-US rose 12% to Rs 440 Cr.
Original exchange filing (PDF)
More announcements from Alembic Pharmaceuticals Ltd
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Binimetinib Tablets, 15 mg and 45 mg. 路 15 Nov 2026
- Please find attached herewith the Transcript of Post Results Conference Call held on 4th November, 2026. 路 10 Nov 2026
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). 路 05 Nov 2026
- Please find attached Audio Recording of Investor Call. 路 05 Nov 2026
- Please find attached intimation under Regulation 30(5) of SEBI (LODR) Regulations, 2015. 路 04 Nov 2026
- Please find attached Press Release 路 04 Nov 2026
- Please find attached Investor Presentation for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
- Please find attached Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
